H.C. Wainwright placed the firm’s Buy rating on Ocuphire Pharma (OCUP) under review saying the acquisition of Opus Genetics starts a new chapter.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUP: